[Comparison of the effectiveness of two different pharmacologic approaches to prevent intraoperative floppy iris syndrome].
OBJECTIVE
To compare the effectiveness of two strategies to prevent the appearance of intraoperative floppy iris syndrome (IFIS) in patients exposed to a-blockers.


METHODS
We compared retrospectively the presence and severity of the appearance of IFIS in 29 patients subjected to cataract surgery, establishing two groups of 12 patients (22 eyes) and 17 patients (33 eyes). The strategy applied to group one consisted of suspending the exposure to a-blockers for at least one week prior to the intervention, the topical application of 1% atropine three times a day for two days before the intervention and the use of intracameral lidocaine. The strategy for group two consisted of suspending use of the drug for at least one week before the intervention and the intracameral application at the beginning of surgery of a solution of physiological serum, adrenaline and lidocaine.


RESULTS
Six patients from group one showed no evidence of IFIS, 2 exhibited bilateral mild symptoms, 2 bilateral moderate and 2 unilateral severe symptoms of IFIS. In total, 45.5% eyes suffered from IFIS. In group two, only 3 eyes (9.1%) from 2 patients exhibited mild symptoms. Statistical analysis showed a significant difference between both groups (p=0.002). If only those exhibiting moderate and severe symptoms are taken into account the result was highly statistically significant (p=0.0002).


CONCLUSIONS
The study shows a greater statistical effectiveness of the strategy applied to group two compared to the strategy applied to group one (Arch Soc Esp Oftalmol 2009; 84: 549-556).
Pérez-Silguero
D
D
Sección de polo anterior, Centro Insular de Oftalmología (CIOF), Las Palmas de Gran Canaria, España. dpsilguero@msn.com
Ramallo-Fariña
Y
Y
Pérez-Silguero
M A
MA
Jiménez-García
A
A
Peñate-Valdivielso
S
S
Pérez-Hernández
F R
FR
D000317:Adrenergic alpha-Antagonists; D002387:Cataract Extraction; D018890:Chemoprevention; D005260:Female; D006801:Humans; D007431:Intraoperative Complications / Q000139:chemically induced / Q000517:prevention & control*; D007499:Iris Diseases / Q000139:chemically induced / Q000517:prevention & control*; D008297:Male; D012189:Retrospective Studies
D000317:Adrenergic alpha-Antagonists